Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
A coalition of state attorneys general, including those in Pennsylvania and New Jersey, has reached agreements with two ...
In a world where weight management is increasingly prioritized, appetite suppressants have gained immense popularity for ...
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...
Dr. Whit Roberts of Health Utah says he is concerned about the financial costs and health risks potentially posed by popular ...
Despite needing FDA clearance to be on the shelves of your local pharmacy, some popular medicines probably don't work.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback